MPDL3280A Treatment in Patients With Locally Advance or Metastatic Non-small Cell Lung, Cancer of the Urinary Tract and Triple Negative Breast Cancer After or During Investigational Imaging

Trial Profile

MPDL3280A Treatment in Patients With Locally Advance or Metastatic Non-small Cell Lung, Cancer of the Urinary Tract and Triple Negative Breast Cancer After or During Investigational Imaging

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2018

At a glance

  • Drugs Atezolizumab (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Non-small cell lung cancer; Solid tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jun 2018 Planned number of patients changed from 40 to 79.
    • 13 Jun 2018 Planned End Date changed from 1 Sep 2019 to 1 Dec 2020.
    • 13 Jun 2018 Planned primary completion date changed from 1 Sep 2019 to 1 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top